A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with advanced solid malignancies

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2157-2166

  Siu, Lillian L ^a   Rowinsky, Eric K ^a   Hammond, Lisa A ^a   Weiss, Geoffrey R ^a   Hidalgo, Manuel ^a   Clark, Gary M ^a   Moczygemba, Judy ^a   Choi, Les ^c   Linnartz, Ron ^c   Barbet, Nicholas C ^c   Sklenar, Ivo T ^c   Capdeville, Renaud ^c   Gan, Gregory ^b   Porter, Carl W ^b   Von Hoff, Daniel D ^a   Eckhardt, S Gail ^a  

^a CTRC Institute for Drug Development   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMIDINO 1 INDANONE 2' AMIDINOHYDRAZONE; ADENOSYLMETHIONINE DECARBOXYLASE INHIBITOR; ANTINEOPLASTIC AGENT; POLYAMINE; SAM 486A; UNCLASSIFIED DRUG; 4-AMIDINOINDAN-1-ONE 2'-AMIDINOHYDRAZONE; ADENOSYLMETHIONINE DECARBOXYLASE; AMIDINE; ENZYME INHIBITOR; INDAN DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; ENZYME INHIBITION; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; POLYAMINE SYNTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; TUMOR BIOPSY; VOMITING; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; ENZYMOLOGY; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; METABOLISM; MIDDLE AGED; NEOPLASM;

ADENOSYLMETHIONINE DECARBOXYLASE; ADULT; AGED; AMIDINES; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMAN; INDANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGE; NEOPLASMS; POLYAMINES; HUMANS; MIDDLE AGED;

EID: 0035992316     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Polymnine metabolism and its importance in neoplastic growth and as a target for chemotherapy
2. Polyamines: From molecular biology to clinical applications
3. Polyamine inhibitors and analogues as potential anticancer agents
4. Development of difluoromethylornithine (DFMO) as a chemoprevention agent
5. Methylglyoxal-bis(guanylhydra zone) (methyl-GAG): Current status and future prospects
6. Morphological evidence for an antimitochondrial action of methylglyoxal-bis(guanylhydrazone)
7. The generality of methylglyoxal-bis(guanylhydrazone) (MGBG)-induced mitochondrial damage and the dependence of this effect on proliferative activity
8. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity
9. Biochemical and growth-modulatory effects of the new S-adenosylmethionine decarboxylase inhibitor CGP 48664 in malignant and immortalized normal breast epithelial cells in culture
10. Human prostatic carcinoma cell lines display altered regulation of polyamine transport in response to polyamine analogs and inhibitors
11. CGP 48664, a potent and specific S-adenosylmethionine decarboxylase inhibitor: Effects on regulation and stability of the enzyme
12. Stable amplification of the S-adenosylmethionine decarboxylase gene in Chinese hamster ovary cells
13. In vivo growth inhibition of L1210 leukemia by 4-amidinoindan-1-one 2′-amidinohydrazone (CGP 48664A), a new inhibitor of S-adenosylmethionine decarboxylase
14. Systemic administration of 4-amidinoindanon-1-(2′-amidino)/hydrazone, a new inhibitor of S-adenosylmethionine decarboxylase, produces cytostasis of human prostate cancer in athymic nude mice
15. Treatment of nude mice with 4-amidinoindanon-1-(2′amidino) hydrazone, a new S-adenosylmethionine decarboxylase inhibitor, delays growth and inhibits metastasis of human melanoma cells
16. Antitumor activity of the S-adenosylmethionine decarboxylase (SAMDC) inhibitor SAM486 alone and in combination with conventional cytotoxic agents
17. Phase I dose escalation and pharmacokinetic study of CGP 48664, a new S-adenosylmethionine decarboxylase (SAMDC) inhibitor, administered in continuous infusion over 5 days in cancer patients with solid tumors
18. Bruntsch pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors
19. Practical modifications of the continual reassessment method for Phase I cancer clinical trials
20. Continual reassessment method: A practical design for Phase I clinical trials in cancer
21. The continual reassessment method (CRM) for dose escalation in Phase I trials in San Antonio does not result in more rapid study completion
22. Guidelines for reporting of adverse drug reactions
23. Automated quantitative determination of a new polyamine biosynthesis inhibitor (CGP 48664) and a potential metabolite in human and animal plasma by high-performance liquid chromatography
24. Cellular characterization of a new irreversible inhibitor of S-adenosylmethionine decarboxylase and its use in determining the relative abilities of individual polyamines to sustain growth and viability of L1210 cells
25. Ultrastructural changes in mitochondria of intestinal epithelium of rodents treated with methylglyoxal-bis(guanylhydrazone)
26. Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in Phase I studies in patients with advanced cancers
27. S-adenosylmethionine decarboxylase activity and utilization of exogenous putrescine are enhanced in colon cancer cells stimulated to grow by EGF
28. Polyamines in colorectal cancer. Evaluation of polyamine concentrations in the colon tissue, serum, and urine of 50 patients with colorectal cancer
29. MGBG: Teaching an old drug new tricks
30. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: Results from a multicenter Phase II trial